Lund-based MedVasc raises funding ahead of FDA submission
Summary
MedVasc AB, a medical technology company based in Lund, Sweden, has closed a 915K (SEK 10 million) funding round to support the final development phase of its Solutio device and preparations for U.S. FDA regulatory submission. The funds will be used to finalize the device design, conduct required testing, and prepare documentation for FDA clearance, which the company aims to submit in the first half of 2026. MedVasc plans to initiate an additional financing round later in 2025 to support further clinical and preclinical work tied to the FDA process.MedVasc AB is a medical technology company specializing in innovations for vascular procedures. The company has completed a first-in-man clinical study and, as of 2023, has initiated the FDA 510(k) process as part of its regulatory strategy for entering the U.S. market.We are very pleased with the continued confidence from our investors, says Cathrin Johansson, CEO of MedVasc AB. This investment gives us the opportunity to take decisive steps towards reaching the US market, which is an important milestone in our growth journey.Solutio is designed to enable safe and precise local anesthesia during minimally invasive vascular procedures (compatible with thermal ablation treatment fibers), offering a new level of control and patient comfort for clinicians treating chronic venous disorders.The financing round attracted both existing owners and new investors, demonstrating continued strong confidence in MedVascs technology and market potential.In addition, MedVasc will raise an additional round during 2025 for investments in clinical and preclinical activities required for FDA clearance.